Remove 2024 Remove Packaging Remove Pharmaceutical Companies
article thumbnail

Sustainability continues to steer pharmaceutical packaging market

European Pharmaceutical Review

The worldwide pharmaceutical container packaging market is expected to rise in revenue from $104.12 billion by 2033, according to a study published by Towards Packaging. percent between 2024 and 2033. Specifically, the “high quality of biodegradable and recyclable packaging materials” are driving the market.

article thumbnail

CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024

Pharmaceutical Technology

Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value from 2023 to 2024, reaching a total deal value of $2.81bn, according to GlobalData’s Pharma Intelligence Center Deals Database. ASOs accounted for more than half ($3.54

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

European Commission authorises one of first ustekinumab biosimilars in Europe

European Pharmaceutical Review

“approval [of Pyzchiva ® (biosimilar ustekinumab)] of is a crucial step towards offering European patients an additional safe and effective treatment option” Pharmaceutical company Sandoz has announced that the European Commission (EC) has granted marketing authorisation for Pyzchiva ® (biosimilar ustekinumab ).

article thumbnail

RFK Jr looks to alter rare disease regulation by fast-tracking drug approvals

Pharmaceutical Technology

In one of the fierier remarks from the roundtable, RFK Jr said: “At every level, doctors, other providers, our hospitals, the pharmaceutical companies, the insurance companies, all make money by keeping us sick. We need to fundamentally change that so that we are focusing on curing disease and making people better.”

article thumbnail

Ireland is open: The biologics boom boosting the Irish economy

pharmaphorum

With an attractive corporate tax rate and the youngest workforce in the EU, Ireland continues to be a popular destination for life science companies to settle. Although cities such as Dublin and Cork were the traditional centres for pharmaceutical companies, a new wave of regional investment is happening across the country.

Packaging 124
article thumbnail

Investing in biologics excellence

pharmaphorum

Accordingly, pharmaceutical companies are expected to up their investment in this area, both in terms of production infrastructure and expertise.”. “This trend will continue in the near future with a steady increase in market demand over the coming years, alongside further development in cell and gene therapies,” says Magnelli.

article thumbnail

EC’s proposed pharma reforms spark industry discontent

Pharmaceutical Technology

The recent legislative reform proposals put forward by the European Commission (EC) have sparked significant discontent among pharmaceutical companies. While a handful of incentives are offered by the reform package, they are overshadowed by the potential drawbacks for the innovative sector.